Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $23.2 million.

  • Mimedx's Net Cash Flow rose 1745.0% to $23.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.3 million, marking a year-over-year increase of 60282.28%. This contributed to the annual value of $23.3 million for FY2024, which is 357.67% down from last year.
  • As of Q3 2025, Mimedx's Net Cash Flow stood at $23.2 million, which was up 1745.0% from $12.4 million recorded in Q2 2025.
  • In the past 5 years, Mimedx's Net Cash Flow registered a high of $23.2 million during Q3 2025, and its lowest value of -$32.7 million during Q1 2024.
  • Moreover, its 5-year median value for Net Cash Flow was $715000.0 (2022), whereas its average is $2.5 million.
  • In the last 5 years, Mimedx's Net Cash Flow tumbled by 131609.2% in 2022 and then soared by 1044039.74% in 2024.
  • Over the past 5 years, Mimedx's Net Cash Flow (Quarter) stood at -$11.4 million in 2021, then skyrocketed by 36.34% to -$7.3 million in 2022, then soared by 97.92% to -$151000.0 in 2023, then skyrocketed by 10440.4% to $15.6 million in 2024, then soared by 48.67% to $23.2 million in 2025.
  • Its last three reported values are $23.2 million in Q3 2025, $12.4 million for Q2 2025, and $2.0 million during Q1 2025.